keywords photodynamic therapy
Recently Published Documents


TOTAL DOCUMENTS

5
(FIVE YEARS 1)

H-INDEX

1
(FIVE YEARS 0)

2021 ◽  
Vol 12 (1) ◽  
pp. e15-e15
Author(s):  
Ardavan Etemadi ◽  
Mehdi Hamidain ◽  
Steven Parker ◽  
Nasim Chiniforush

Introduction: The aim of this article was to evaluate reports in the scientific literature that used antimicrobial photodynamic therapy (aPDT) with a blue light source and curcumin and riboflavin as photosensitizers in the management of periodontitis. Methods: The search was conducted in electronic databases, including PubMed, Web of Science, and Scopus, with the keywords "photodynamic therapy", "antimicrobial photodynamic therapy", "laser activated disinfection", "photoactivated disinfection", "light activated disinfection" "LED", "Periodontitis", "Curcumin", "Riboflavin", and "periodontitis" from 2012 to 2020. Results: After evaluating a total of 24 relevant articles, 13 articles were selected, full texts were read, and the data were extracted and placed in a table. Conclusion: Reviewing articles showed that curcumin as a photosensitizer activated by a blue wavelength is effective in the elimination of the various bacterial species involved in periodontal disease, and to the best of our knowledge, there is no study that has shown this substance does not reduce bacteria. According to the result of the articles, riboflavin as a photosensitizer activated by blue light can reduce bacteria that are involved in periodontitis, but other studies have reported that blue light alone can also reduce bacteria significantly. Therefore, more in-vitro and clinical trial studies are needed to give a more conclusive opinion on the effectiveness of riboflavin as a photosensitizer in the treatment of periodontitis.



2020 ◽  
Vol 86 (1) ◽  
pp. 69-77
Author(s):  
V.V. Dunaevskaya ◽  
T.F. Tatarchuk ◽  
O.V. Zanko

A comprehensive approach that includes the treatment of background and precancerous diseases of the vulva by photodynamic therapy and plasma therapy as rehabilitation therapy was developed. The method’s effectiveness was evaluated. The study is also aimed at evaluating the effectiveness of plasma therapy after treatment of background and precancerous diseases of the vulva by photodynamic therapy. The work is based on the study results of 60 patients aged 32 to 70 years old, mean age was (53.3+3.6) years, with a morphologically verified diagnosis of vulvar intraepithelial neoplasia, mixed vulvar dystrophy (Lichen sclerosus et atrophicus, squamous cell hyperplasia), which were divided into two groups. Patients of both groups underwent photodynamic therapy using an intravenous photosensitizer «Fotolon®» (RUE «Belmedpreparaty», Republic of Belarus), which is a complex of chlorine ебс trisodium salt with low molecular weight polyvinylpyrrolidone. The session of photodynamic therapy was performed 3^1 hours after the end of the FS infusion using a universal laser coagulator «Likar-Hirurg (Surgeon)» («Photonica Plus», Ukraine, A-660 nm). Plasma therapy was performed for patients of group 2 after photodynamic therapy. It has been established that the use of photodynamic therapy and plasma therapy increases the effect of treatment of background and precancerous diseases of the vulva, accelerates the period of damaged tissues regeneration and rehabilitation of patients twice and prolongs the recurrence-free period of the disease. Keywords: photodynamic therapy, plasma therapy, precancerous diseases of the vulva.



2020 ◽  
pp. 491-497
Author(s):  
A.A. SUFIANOV ◽  
◽  
D.A. MURZAEVA ◽  
I.S. SHELYAGIN ◽  
R.A. SUFIANOV ◽  
...  

World literature data dedicated to the problem of application of photodynamic therapy (PDT) in the neurooncology has been studied and analyzed, and also the prospects for development and improvement of surgical treatment for malignant neoplasms of CNS are covered. The following databases are used: PubMed, Web of Science, Scopus, MEDLINE, EMBASE, Biosis Citation Index, SciELO Citation Index, RSCI. Noted, that PDT treatment of tumors can be widely used in various areas of oncology demonstrating high efficiency and radical value. In particular, the method shows good treatment results for brain glioblastomas. At the same time, the use of modern photosensitizers and methods of delivering pharmaceutical drugs to affected cells in conjunction with the use of fiber optics makes it possible to minimize damage to surrounding tissues and possible neurological deficits. Keywords: Photodynamic therapy, CNS tumors, minimally invasive interventions.



2018 ◽  
Vol 67 (4) ◽  
pp. 113-130
Author(s):  
Anna Romiszewska ◽  
Aneta Bombalska

5-aminolevulinic acid (5-ALA) is used as a drug in the photodynamic therapy (PDT) and photodynamic diagnosis (PDD) of cancer. Combined with irradiation at the appropriate wavelength, it is used as a photosensitizer precursor to identify/kill tumour cells. In cells, 5-aminolevulinic acid is converted to protoporphyrin IX (PpIX), which is the precursor of hemin. Internal application of 5-ALA induces the overproduction of the endogenous photosensitizer, PpIX, which can subsequently be activated by light at the appropriate wavelength. 5-ALA can be applied internally to trans-mutated areas or be injected directly into them. Chemical derivatives of 5ALA have the potential to improve bioavailability, enhance stability and lead to better therapeutic outcomes for treated patients. 5-ALA is currently the most commonly used drug in the photodynamic therapy and diagnosis (PDT/PDD) of cancers. Keywords: photodynamic therapy, photodynamic diagnosis, 5-aminolevulinic acid (5- ALA), esters of 5-aminolevulinic acid, cancer.



1997 ◽  
Vol 75 (2) ◽  
pp. 99-119 ◽  
Author(s):  
James William Lown

Photodynamic therapy relies on the selective accumulation of photosensitizers within neoplastic tissue, followed by light activation to generate cytotoxic singlet oxygen. At present, PhotofrinTM, a preparation of hematoporphyrin derivatives (HPD) with the bulk of the porphyrin monomers removed, is the only clinically approved photosensitizer. Intravesical administration of Photofrin or HPD has failed to photosensitize bladder tumors. Bladder cancer is the second most common genitourinary malignancy. In 1994 there were an estimated 51 200 cases of bladder cancer with 10 600 deaths in the United States. The predominant histopathology is transitional cell carcinoma, occurring in 90–95% of these cases. Most patients (85%) have superficial disease at the time of initial diagnosis. Superficial bladder cancer is defined as disease involving the mucosa with carcinoma in situ or papillary lesions and invasion limited to submucosa. To address these limitations we have been conducting preclinical studies with perylenequinones (PQs). The majority of our effort has focused on developing and characterizing derivatives of PQs. Following site-directed modifications, we have identified certain congeners that warrant further preclinical development. These compounds are monomeric and do not effect cutaneous photosensitization beyond 24 h. With clinically relevant drug and light doses we have cured >90% of experimental subcutaneous murine tumors. Keywords: photodynamic therapy, perylenequinones, photobiology, photochemistry.



Sign in / Sign up

Export Citation Format

Share Document